Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma

Tan, CR; Derkach, A; Nemirovsky, D; Ciardiello, A; Diamond, B; Hultcrantz, M; Hassoun, H; Mailankody, S; Shah, UR; Maclachlan, K; Patel, D; Lahoud, OB; Landau, HJ; Chung, DJ; Shah, GL; Scordo, M; Giralt, SA; Lesokhin, A; Usmani, SZ; Landgren, O; Korde, N

Tan, CR; Korde, N (通讯作者)，Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, New York, NY 10065 USA.

BLOOD CANCER JOURNAL, 2023; 13 (1):

Abstract

Lenalidomide and dexamethasone with bortezomib (VRd) or carfilzomib (KRd) are commonly used induction regimens in the U.S. This single-center, retrosp......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索